SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 03/10/2025 at 21:09, 1 year ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/08/2025 at 19:05, 1 year ago

Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid

Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
PRESS RELEASE

published on 03/08/2025 at 19:00, 1 year ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU

Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission
BRIEF

published on 02/25/2025 at 07:05, 1 year 1 month ago

Sarclisa Gains Approval in Japan for Multiple Myeloma Treatment

Multiple Myeloma Sarclisa Approval Sanofi Oncology Japan Healthcare IMROZ Study
PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 1 month ago

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for newly diagnosed multiple myeloma patients, offering new treatment options based on positive IMROZ phase 3 study results

Oncology Japan Multiple Myeloma Sarclisa IMROZ Study
PRESS RELEASE

published on 02/24/2025 at 21:27, 1 year 1 month ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 02/22/2025 at 08:35, 1 year 1 month ago

Sanofi-Teva: Duvakitug Promises for Inflammatory Bowel Diseases

Ulcerative Colitis Crohn's Disease Duvakitug RELIEVE UCCD Sanofi-Teva
PRESS RELEASE

published on 02/22/2025 at 08:30, 1 year 1 month ago

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
Sanofi and Teva Pharmaceuticals present new detailed data from the RELIEVE UCCD study on duvakitug's efficacy in ulcerative colitis and Crohn's disease at ECCO 2025, demonstrating potential for phase 3 program in H2 2025

Ulcerative Colitis Sanofi Teva Pharmaceuticals Crohn's Disease RELIEVE UCCD Study
BRIEF

published on 02/19/2025 at 07:35, 1 year 1 month ago

Sanofi and CD&R Finalize Opella Share Purchase Agreement

Share Purchase Regulatory Approvals Sanofi CD&R Opella
PRESS RELEASE

published on 02/19/2025 at 07:30, 1 year 1 month ago

Press Release: Sanofi and CD&R sign Opella share purchase agreement
Sanofi and CD&R sign share purchase agreement for Opella, with Bpifrance as minority shareholder. Transaction expected to close in Q2 2025, subject to regulatory approvals

Share Purchase Agreement Sanofi Bpifrance CD&R Opella

Published on 03/26/2026 at 16:20, 3 hours 31 minutes ago

ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 14:05, 5 hours 46 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 6 hours 51 minutes ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 6 hours 51 minutes ago

GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 6 hours 52 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance

View all ACCESSWIRE

Published on 03/26/2026 at 19:20, 31 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 38 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 42 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:57, 54 minutes ago

DSH-Director/PDMR Shareholding
Published on 03/26/2026 at 18:29, 1 hour 22 minutes ago

IEVA GROUP: IEVA Group is listing on Euronext Growth® Paris to accelerate its growth and innovation strategy

View all EQS

Published on 03/26/2026 at 18:17, 1 hour 34 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 17:45, 2 hours 6 minutes ago

Cegedim: profitability continues to improve
Published on 03/26/2026 at 08:57, 10 hours 54 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 12 hours 21 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:53, 1 day ago

LNA SANTE : 2025 Annual Results

View all LES ECHOS COMFI WIRE

News